Skip to main content
Key Specialties
Anesthesiology Cardiology Dermatology Diabetology Endocrinology Gastroenterology and Hepatology General Medicine Geriatrics Hematology Infectious Diseases Internal Medicine Nephrology Neurology Obstetrics and Gynecology Oncology Ophthalmology Pediatrics Psychiatry Radiology Respiratory Medicine Rheumatology Surgery Urology
Congress Coverage
ASH 2024 Annual Meeting 2024 ESMO Congress 2024 ERS Congress 2024 EASD Congress 2024 ESC Congress 2024 EAN Congress 2024 ASCO Annual Meeting 2024 ACC Congress
Clinical Collections
Women’s Health Knowledge Hub Advances in Alzheimer’s
Video

Keynote series | Spotlight on managing health in obesity

Obesity is a major contributor to cardiorenal metabolic disease, but its impact extends throughout the body. Understand how obesity can affect other organ systems and impact treatment, and whether weight-loss measures improve outcomes.

Launching: Thursday 24th April 2025
 
ADVANCED SEARCH
Log in
Top
BioDrugs
Published in:

11-04-2024 | Antibiotic | Review Article

CRISPR-Cas System: A New Dawn to Combat Antibiotic Resistance

Authors: Muhammad Shahzad Rafiq, Muhammad AbuBakar Shabbir, Ahmed Raza, Shoaib Irshad, Andleeb Asghar, Muhammad Kashif Maan, Mushtaq Ahmed Gondal, Haihong Hao

Published in: BioDrugs | Issue 3/2024

Login to get access

Abstract

Antimicrobial resistance (AMR) can potentially harm global public health. Horizontal gene transfer (HGT), which speeds up the emergence of AMR and increases the burden of drug resistance in mobile genetic elements (MGEs), is the primary method by which AMR genes are transferred across bacterial pathogens. New approaches are urgently needed to halt the spread of bacterial diseases and antibiotic resistance. Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR), an RNA-guided adaptive immune system, protects prokaryotes from foreign DNA like plasmids and phages. This approach may be essential in limiting horizontal gene transfer and halting the spread of antibiotic resistance. The CRISPR-Cas system has been crucial in identifying and understanding resistance mechanisms and developing novel therapeutic approaches. This review article investigates the CRISPR-Cas system’s potential as a tool to combat bacterial AMR. Antibiotic-resistant bacteria can be targeted and eliminated by the CRISPR-Cas system. It has been proven to be an efficient method for removing carbapenem-resistant plasmids and regaining antibiotic susceptibility. The CRISPR-Cas system has enormous potential as a weapon against bacterial AMR. It precisely targets and eliminates antibiotic-resistant bacteria, facilitates resistance mechanism identification, and offers new possibilities in diagnostics and therapeutics.
Literature
1.
2.
Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet Lond Engl. 2022;399:629–55.CrossRef
3.
Murray, C. J. L. et al.Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet Lond Engl. 2022;399:629–55.
4.
Chung M, Yeh I, Sung L, Wu M, Chao Y, Ng I, et al. Enhanced integration of large DNA into E. coli chromosome by CRISPR/Cas9. Biotechnol Bioeng. 2017;114:172–83.PubMedCrossRef
5.
6.
Shetty VP, Akshay SD, Rai P, Deekshit VK. Integrons as the potential targets for combating multidrug resistance in Enterobacteriaceae using CRISPR- Cas9 technique. J Appl Microbiol. 2023;134: lxad137.PubMedCrossRef
7.
Wu Z-Y, Huang Y-T, Chao W-C, Ho S-P, Cheng J-F, Liu P-Y. Reversal of carbapenem-resistance in Shewanella algae by CRISPR/Cas9 genome editing. J Adv Res. 2019;18:61–9.PubMedPubMedCentralCrossRef
8.
Lin DM, Koskella B, Lin HC. Phage therapy: an alternative to antibiotics in the age of multi-drug resistance. World J Gastrointest Pharmacol Ther. 2017;8:162–73.PubMedPubMedCentralCrossRef
9.
Janik E, Niemcewicz M, Ceremuga M, Krzowski L, Saluk-Bijak J, Bijak M. Various aspects of a gene editing system—crispr–cas9. Int J Mol Sci. 2020;21:9604.PubMedPubMedCentralCrossRef
10.
He Y-Z, Kuang X, Long T-F, Li G, Ren H, He B, et al. Re-engineering a mobile-CRISPR/Cas9 system for antimicrobial resistance gene curing and immunization in Escherichia coli. J Antimicrob Chemother. 2022;77:74–82.CrossRef
11.
12.
Kim J-S, Cho D-H, Park M, Chung W-J, Shin D, Ko KS, et al. CRISPR/Cas9-mediated re-sensitization of antibiotic-resistant Escherichia coli harboring extended-spectrum β-lactamases. J Microbiol Biotechnol. 2016;26:394–401.PubMedCrossRef
13.
Mojica FJ, Díez-Villaseñor C, Soria E, Juez G. Biological significance of a family of regularly spaced repeats in the genomes of Archaea, Bacteria and mitochondria. Mol Microbiol. 2000;36:244–6.PubMedCrossRef
14.
Jansen R, van Embden JD, Gaastra W, Schouls LM. Identification of genes that are associated with DNA repeats in prokaryotes. Mol Microbiol. 2002;43:1565–75.PubMedCrossRef
15.
Hille F, Charpentier E. CRISPR-Cas: biology, mechanisms and relevance. Philos Trans R Soc B Biol Sci. 2016;371:20150496.CrossRef
16.
Nuñez JK, Kranzusch PJ, Noeske J, Wright AV, Davies CW, Doudna JA. Cas1–Cas2 complex formation mediates spacer acquisition during CRISPR–Cas adaptive immunity. Nat Struct Mol Biol. 2014;21:528–34.PubMedPubMedCentralCrossRef
17.
18.
Teng M, Yao Y, Nair V, Luo J. Latest advances of virology research using CRISPR/Cas9-based gene-editing technology and its application to vaccine development. Viruses. 2021;13:779.PubMedPubMedCentralCrossRef
19.
20.
Abudayyeh OO, Gootenberg JS, Konermann S, Joung J, Slaymaker IM, Cox DB, et al. C2c2 is a single-component programmable RNA-guided RNA-targeting CRISPR effector. Science. 2016;353: aaf5573.PubMedPubMedCentralCrossRef
21.
Alduhaidhawi AHM, AlHuchaimi SN, Al-Mayah TA, Al-Ouqaili MT, Alkafaas SS, Muthupandian S, et al. Prevalence of CRISPR-cas systems and their possible association with antibiotic resistance in Enterococcus faecalis and Enterococcus faecium collected from hospital wastewater. Infect Drug Resist. 2022;15:1143–54.PubMedPubMedCentralCrossRef
22.
Hullahalli K, Rodrigues M, Schmidt BD, Li X, Bhardwaj P, Palmer KL. Comparative analysis of the orphan CRISPR2 locus in 242 Enterococcus faecalis strains. PLoS One. 2015;10: e0138890.PubMedPubMedCentralCrossRef
23.
24.
Burley KM, Sedgley CM. CRISPR-Cas, a prokaryotic adaptive immune system, in endodontic, oral, and multidrug-resistant hospital-acquired Enterococcus faecalis. J Endod. 2012;38:1511–5.PubMedCrossRef
25.
26.
Gholizadeh P, Aghazadeh M, Ghotaslou R, Rezaee MA, Pirzadeh T, Cui L, et al. Role of CRISPR-Cas system on antibiotic resistance patterns of Enterococcus faecalis. Ann Clin Microbiol Antimicrob. 2021;20:1–12.CrossRef
27.
Zhou Y, Yang Y, Li X, Tian D, Ai W, Wang W, et al. Exploiting a conjugative endogenous CRISPR-Cas3 system to tackle multidrug-resistant Klebsiella pneumoniae. EBioMedicine. 2023;88: 104445.PubMedPubMedCentralCrossRef
28.
Sinkunas T, Gasiunas G, Fremaux C, Barrangou R, Horvath P, Siksnys V. Cas3 is a single-stranded DNA nuclease and ATP-dependent helicase in the CRISPR/Cas immune system. EMBO J. 2011;30:1335–42.PubMedPubMedCentralCrossRef
29.
30.
Selle K, Fletcher JR, Tuson H, Schmitt DS, McMillan L, Vridhambal GS, et al. In Vivo Targeting of Clostridioides difficile Using Phage-Delivered CRISPR-Cas3 Antimicrobials. MBio. 2020;11: e00019-20.PubMedPubMedCentralCrossRef
31.
Yosef I, Manor M, Kiro R, Qimron U. Temperate and lytic bacteriophages programmed to sensitize and kill antibiotic-resistant bacteria. Proc Natl Acad Sci. 2015;112:7267–72.PubMedPubMedCentralCrossRef
32.
33.
Hao M, He Y, Zhang H, Liao X-P, Liu Y-H, Sun J, et al. CRISPR-Cas9-mediated carbapenemase gene and plasmid curing in carbapenem-resistant enterobacteriaceae. Antimicrob Agents Chemother. 2020;64:e00843-e920.PubMedPubMedCentralCrossRef
34.
Kyrou K, Hammond AM, Galizi R, Kranjc N, Burt A, Beaghton AK, et al. A CRISPR–Cas9 gene drive targeting doublesex causes complete population suppression in caged Anopheles gambiae mosquitoes. Nat Biotechnol. 2018;36:1062–6.PubMedPubMedCentralCrossRef
35.
Shahriar SA, Islam MN, Chun CNW, Rahim MA, Paul NC, Uddain J, et al. Control of plant viral diseases by CRISPR/Cas9: resistance mechanisms, strategies and challenges in food crops. Plants. 2021;10:1264.PubMedPubMedCentralCrossRef
36.
Hazafa A, Mumtaz M, Farooq MF, Bilal S, Chaudhry SN, Firdous M, et al. CRISPR/Cas9: a powerful genome editing technique for the treatment of cancer cells with present challenges and future directions. Life Sci. 2020;263: 118525.PubMedPubMedCentralCrossRef
37.
38.
Hamilton TA, Pellegrino GM, Therrien JA, Ham DT, Bartlett PC, Karas BJ, et al. Efficient inter-species conjugative transfer of a CRISPR nuclease for targeted bacterial killing. Nat Commun. 2019;10:4544.PubMedPubMedCentralCrossRef
39.
Pouillot F, Chomton M, Blois H, Courroux C, Noelig J, Bidet P, et al. Efficacy of bacteriophage therapy in experimental sepsis and meningitis caused by a clone O25b:H4-ST131 Escherichia coli strain producing CTX-M-15. Antimicrob Agents Chemother. 2012;56:3568–75.PubMedPubMedCentralCrossRef
40.
Aslam B, Rasool M, Idris A, Muzammil S, Alvi RF, Khurshid M, et al. CRISPR-Cas system: a potential alternative tool to cope antibiotic resistance. Antimicrob Resist Infect Control. 2020;9:131.PubMedPubMedCentralCrossRef
41.
Meeske AJ, Nakandakari-Higa S, Marraffini LA. Cas13-induced cellular dormancy prevents the rise of CRISPR-resistant bacteriophage. Nature. 2019;570:241–5.PubMedPubMedCentralCrossRef
42.
43.
Kiga K, Tan X-E, Ibarra-Chávez R, Watanabe S, Aiba Y, Sato’o Y, et al. Development of CRISPR-Cas13a-based antimicrobials capable of sequence-specific killing of target bacteria. Nat Commun. 2020;11:2934.PubMedPubMedCentralCrossRef
44.
Wan F, Draz MS, Gu M, Yu W, Ruan Z, Luo Q. Novel strategy to combat antibiotic resistance: a sight into the combination of CRISPR/Cas9 and nanoparticles. Pharmaceutics. 2021;13:352.PubMedPubMedCentralCrossRef
45.
Pyne ME, Moo-Young M, Chung DA, Chou CP. Coupling the CRISPR/Cas9 system with lambda red recombineering enables simplified chromosomal gene replacement in Escherichia coli. Appl Environ Microbiol. 2015;81:5103–14.PubMedPubMedCentralCrossRef
46.
47.
Yang W, Yan J, Zhuang P, Ding T, Chen Y, Zhang Y, et al. Progress of delivery methods for CRISPR-Cas9. Expert Opin Drug Deliv. 2022;19:913–26.PubMedCrossRef
48.
49.
Wang Y, Qi T, Liu J, Yang Y, Wang Z, Wang Y, et al. A highly specific CRISPR-Cas12j nuclease enables allele-specific genome editing. Sci Adv. 2023;9: eabo6405.PubMedPubMedCentralCrossRef
50.
Pantoja Angles A, Ali Z, Mahfouz M. CS-cells: a CRISPR-Cas12 DNA device to generate chromosome-shredded cells for efficient and safe molecular biomanufacturing. ACS Synth Biol. 2022;11:430–40.PubMedCrossRef
51.
Khambhati K, Bhattacharjee G, Gohil N, Dhanoa GK, Sagona AP, Mani I, et al. Phage engineering and phage-assisted CRISPR-Cas delivery to combat multidrug-resistant pathogens. Bioeng Transl Med. 2022;8: e10381.PubMedPubMedCentralCrossRef
52.
Rodrigues M, McBride SW, Hullahalli K, Palmer KL, Duerkop BA. Conjugative delivery of CRISPR-Cas9 for the selective depletion of antibiotic-resistant enterococci. Antimicrob Agents Chemother. 2019;63:e01454-e1519.PubMedPubMedCentralCrossRef
53.
Nguyen GT, Dhingra Y, Sashital DG. Miniature CRISPR-Cas12 endonucleases–programmed DNA targeting in a smaller package. Curr Opin Struct Biol. 2022;77: 102466.PubMedPubMedCentralCrossRef
54.
Yeh T-K, Jean S-S, Lee Y-L, Lu M-C, Ko W-C, Lin H-J, et al. Bacteriophages and phage-delivered CRISPR-Cas system as antibacterial therapy. Int J Antimicrob Agents. 2022;59: 106475.PubMedCrossRef
55.
Lam KN, Spanogiannopoulos P, Soto-Perez P, Alexander M, Nalley MJ, Bisanz JE, et al. Phage-delivered CRISPR-Cas9 for strain-specific depletion and genomic deletions in the gut microbiome. Cell Rep. 2021;37: 109930.PubMedPubMedCentralCrossRef
56.
Fage C, Lemire N, Moineau S. Delivery of CRISPR-Cas systems using phage-based vectors. Curr Opin Biotechnol. 2021;68:174–80.PubMedCrossRef
57.
Deng H, Huang W, Zhang Z. Nanotechnology based CRISPR/Cas9 system delivery for genome editing: progress and prospect. Nano Res. 2019;12:2437–50.CrossRef
58.
Rodríguez-Rodríguez DR, Ramírez-Solís R, Garza-Elizondo MA, Garza-Rodríguez MDL, Barrera-Saldaña HA. Genome editing: a perspective on the application of CRISPR/Cas9 to study human diseases (Review). Int J Mol Med. 2019;43:1559–74.PubMedPubMedCentral
59.
Givens BE, Naguib YW, Geary SM, Devor EJ, Salem AK. Nanoparticle-based delivery of CRISPR/Cas9 genome-editing therapeutics. AAPS J. 2018;20:1–22.CrossRef
60.
61.
Huang K, Zapata D, Tang Y, Teng Y, Li Y. In vivo delivery of CRISPR-Cas9 genome editing components for therapeutic applications. Biomaterials. 2022;291: 121876.PubMedPubMedCentralCrossRef
62.
Qin W, Wang H. Delivery of CRISPR-Cas9 into mouse zygotes by electroporation. Methods Mol Biol Clifton NJ. 2019;1874:179–90.CrossRef
63.
Wu Y, Battalapalli D, Hakeem MJ, Selamneni V, Zhang P, Draz MS, et al. Engineered CRISPR-Cas systems for the detection and control of antibiotic-resistant infections. J Nanobiotechnology. 2021;19:401.PubMedPubMedCentralCrossRef
64.
Dhasmana N, Ram G, McAllister KN, Chupalova Y, Lopez P, Ross HF, et al. Dynamics of antibacterial drone establishment in Staphylococcus aureus: unexpected effects of antibiotic resistance genes. MBio. 2021;12:e02083-e2121.PubMedPubMedCentralCrossRef
65.
Abavisani M, Khayami R, Hoseinzadeh M, Kodori M, Kesharwani P, Sahebkar A. CRISPR-Cas system as a promising player against bacterial infection and antibiotic resistance. Drug Resist Updat. 2023;68: 100948.PubMedCrossRef
66.
Huemer M, Mairpady Shambat S, Brugger SD, Zinkernagel AS. Antibiotic resistance and persistence—implications for human health and treatment perspectives. EMBO Rep. 2020;21: e51034.PubMedPubMedCentralCrossRef
67.
Senthilnathan R, Ilangovan I, Kunale M, Easwaran N, Ramamoorthy S, Veeramuthu A, et al. An update on CRISPR-Cas12 as a versatile tool in genome editing. Mol Biol Rep. 2023;50:2865–81.PubMedCrossRef
68.
69.
Song X, Liu C, Wang N, Huang H, He S, Gong C, et al. Delivery of CRISPR/Cas systems for cancer gene therapy and immunotherapy. Adv Drug Deliv Rev. 2021;168:158–80.PubMedCrossRef
70.
Taati Moghadam M, Amirmozafari N, Shariati A, Hallajzadeh M, Mirkalantari S, Khoshbayan A, et al. How phages overcome the challenges of drug resistant bacteria in clinical infections. Infect Drug Resist. 2020;13:45–61.PubMedPubMedCentralCrossRef
71.
Wang Z, Cui W. CRISPR-Cas system for biomedical diagnostic platforms. View. 2020;1:20200008.CrossRef
72.
Tang Y, Gao L, Feng W, Guo C, Yang Q, Li F, et al. The CRISPR–Cas toolbox for analytical and diagnostic assay development. Chem Soc Rev. 2021;50:11844–69.PubMedCrossRef
73.
Padmanaban V, Ranganathan UDK. CRISPR–Cas system and its use in the diagnosis of infectious diseases. Microbiol Res. 2022;263: 127100.PubMedCrossRef
74.
Quan J, Langelier C, Kuchta A, Batson J, Teyssier N, Lyden A, et al. FLASH: a next-generation CRISPR diagnostic for multiplexed detection of antimicrobial resistance sequences. Nucleic Acids Res. 2019;47:e83–e83.PubMedPubMedCentralCrossRef
75.
Haeussler M, Schönig K, Eckert H, Eschstruth A, Mianné J, Renaud J-B, et al. Evaluation of off-target and on-target scoring algorithms and integration into the guide RNA selection tool CRISPOR. Genome Biol. 2016;17:1–12.CrossRef
76.
Yang H, Zhang Y, Teng X, Hou H, Deng R, Li J. CRISPR-based nucleic acid diagnostics for pathogens. Trends Anal Chem. 2023;160: 116980.CrossRef
77.
78.
79.
Arizti-Sanz J, Freije CA, Stanton AC, Petros BA, Boehm CK, Siddiqui S, et al. Streamlined inactivation, amplification, and Cas13-based detection of SARS-CoV-2. Nat Commun. 2020;11:5921.PubMedPubMedCentralCrossRef
80.
Bonini A, Poma N, Vivaldi F, Biagini D, Bottai D, Tavanti A, et al. A label-free impedance biosensing assay based on CRISPR/Cas12a collateral activity for bacterial DNA detection. J Pharm Biomed Anal. 2021;204: 114268.PubMedCrossRef
81.
82.
Nguyen LT, Macaluso NC, Pizzano BLM, Cash MN, Spacek J, Karasek J, et al. A thermostable Cas12b from Brevibacillus leverages one-pot detection of SARS-CoV-2 variants of concern. MedRxiv Prepr Serv Health Sci. 2021;2021.10.15.21265066.
83.
Ge X, Meng T, Tan X, Wei Y, Tao Z, Yang Z, et al. Cas14a1-mediated nucleic acid detectifon platform for pathogens. Biosens Bioelectron. 2021;189: 113350.PubMedCrossRef
84.
Wei Y, Tao Z, Wan L, Zong C, Wu J, Tan X, et al. Aptamer-based Cas14a1 biosensor for amplification-free live pathogenic detection. Biosens Bioelectron. 2022;211: 114282.PubMedCrossRef
85.
Abavisani M, Khayami R, Hoseinzadeh M, Kodori M, Kesharwani P, Sahebkar A. CRISPR-Cas system as a promising player against bacterial infection and antibiotic resistance. Drug Resist Updat Rev Comment Antimicrob Anticancer Chemother. 2023;68: 100948.
86.
Huang M, Zhou X, Wang H, Xing D. Clustered regularly interspaced short palindromic repeats/Cas9 triggered isothermal amplification for site-specific nucleic acid detection. Anal Chem. 2018;90:2193–200.PubMedCrossRef
87.
Xiao G, Zhang S, Liang Z, Li G, Fang M, Liu Y, et al. Identification of Mycobacterium abscessus species and subspecies using the Cas12a/sgRNA-based nucleic acid detection platform. Eur J Clin Microbiol Infect Dis. 2020;39:551–8.PubMedCrossRef
88.
89.
Pouillot F, Chomton M, Blois H, Courroux C, Noelig J, Bidet P, et al. Efficacy of bacteriophage therapy in experimental sepsis and meningitis caused by a clone O25b: H4-ST131 Escherichia coli strain producing CTX-M-15. Antimicrob Agents Chemother. 2012;56:3568–75.PubMedPubMedCentralCrossRef
90.
Sun Q, Wang Y, Dong N, Shen L, Zhou H, Hu Y, et al. Application of CRISPR/Cas9-based genome editing in studying the mechanism of pandrug resistance in Klebsiella pneumoniae. Antimicrob Agents Chemother. 2019;63:e00113-e119.PubMedPubMedCentralCrossRef
91.
Wu X, Zha J, Koffas MA, Dordick JS. Reducing Staphylococcus aureus resistance to lysostaphin using CRISPR-dCas9. Biotechnol Bioeng. 2019;116:3149–59.PubMedCrossRef
92.
Ram G, Ross HF, Novick RP, Rodriguez-Pagan I, Jiang D. Conversion of staphylococcal pathogenicity islands to CRISPR-carrying antibacterial agents that cure infections in mice. Nat Biotechnol. 2018;36:971–6.PubMedPubMedCentralCrossRef
93.
Park JY, Moon BY, Park JW, Thornton JA, Park YH, Seo KS. Genetic engineering of a temperate phage-based delivery system for CRISPR/Cas9 antimicrobials against Staphylococcus aureus. Sci Rep. 2017;7:44929.PubMedPubMedCentralCrossRef
94.
Kang YK, Kwon K, Ryu JS, Lee HN, Park C, Chung HJ. Nonviral genome editing based on a polymer-derivatized CRISPR nanocomplex for targeting bacterial pathogens and antibiotic resistance. Bioconjug Chem. 2017;28:957–67.PubMedCrossRef
95.
Bikard D, Euler CW, Jiang W, Nussenzweig PM, Goldberg GW, Duportet X, et al. Exploiting CRISPR-Cas nucleases to produce sequence-specific antimicrobials. Nat Biotechnol. 2014;32:1146–50.PubMedPubMedCentralCrossRef
96.
Walflor HSM, Lucena ARC, Tuon FF, Medeiros LCS, Faoro H. Resensitization of fosfomycin-resistant Escherichia coli using the CRISPR system. Int J Mol Sci. 2022;23:9175.PubMedPubMedCentralCrossRef
97.
Wan P, Cui S, Ma Z, Chen L, Li X, Zhao R, et al. Reversal of mcr-1-mediated colistin resistance in Escherichia coli by CRISPR-Cas9 system. Infect Drug Resist. 2020;13:1171–8.PubMedPubMedCentralCrossRef
98.
Reuter A, Hilpert C, Dedieu-Berne A, Lematre S, Gueguen E, Launay G, et al. Targeted-antibacterial-plasmids (TAPs) combining conjugation and CRISPR/Cas systems achieve strain-specific antibacterial activity. Nucleic Acids Res. 2021;49:3584–98.PubMedPubMedCentralCrossRef
99.
Tagliaferri TL, Guimarães NR, Pereira MPM, Vilela LFF, Horz H-P, Dos Santos SG, et al. Exploring the potential of CRISPR-Cas9 under challenging conditions: facing high-copy plasmids and counteracting beta-lactam resistance in clinical strains of Enterobacteriaceae. Front Microbiol. 2020;11:578.PubMedPubMedCentralCrossRef
100.
Li P, Wan P, Zhao R, Chen J, Li X, Li J, et al. Targeted elimination of blaNDM-5 gene in Escherichia coli by conjugative CRISPR-Cas9 system. Infect Drug Resist. 2022;15:1707–16.PubMedPubMedCentralCrossRef
101.
102.
Liu H, Li H, Liang Y, Du X, Yang C, Yang L, et al. Phage-delivered sensitisation with subsequent antibiotic treatment reveals sustained effect against antimicrobial resistant bacteria. Theranostics. 2020;10:6310–21.PubMedPubMedCentralCrossRef
103.
Wang T, Liu Y, Sun H-H, Yin B-C, Ye B-C. An RNA-guided Cas9 nickase-based method for universal isothermal DNA amplification. Angew Chem. 2019;131:5436–40.CrossRef
104.
Guk K, Keem JO, Hwang SG, Kim H, Kang T, Lim E-K, et al. A facile, rapid and sensitive detection of MRSA using a CRISPR-mediated DNA FISH method, antibody-like dCas9/sgRNA complex. Biosens Bioelectron. 2017;95:67–71.PubMedCrossRef
105.
Wang X, Xiong E, Tian T, Cheng M, Lin W, Wang H, et al. Clustered regularly interspaced short palindromic repeats/Cas9-mediated lateral flow nucleic acid assay. ACS Nano. 2020;14:2497–508.PubMedCrossRef
106.
You Y, Zhang P, Wu G, Tan Y, Zhao Y, Cao S, et al. Highly specific and sensitive detection of Yersinia pestis by portable Cas12a-UPTLFA platform. Front Microbiol. 2021;12: 700016.PubMedPubMedCentralCrossRef
107.
Ai J-W, Zhou X, Xu T, Yang M, Chen Y, He G-Q, et al. CRISPR-based rapid and ultra-sensitive diagnostic test for Mycobacterium tuberculosis. Emerg Microbes Infect. 2019;8:1361–9.PubMedPubMedCentralCrossRef
108.
Wang Y, Liang X, Xu J, Nan L, Liu F, Duan G, et al. Rapid and ultrasensitive detection of methicillin-resistant Staphylococcus aureus based on CRISPR-Cas12a combined with recombinase-aided amplification. Front Microbiol. 2022;13: 903298.PubMedPubMedCentralCrossRef
109.
Liu X, Qiu X, Xu S, Che Y, Han L, Kang Y, et al. A CRISPR-Cas12a-assisted fluorescence platform for rapid and accurate detection of Nocardia cyriacigeorgica. Front Cell Infect Microbiol. 2022;12: 835213.PubMedPubMedCentralCrossRef
110.
Wang Y, Ke Y, Liu W, Sun Y, Ding X. A one-pot toolbox based on Cas12a/crRNA enables rapid foodborne pathogen detection at attomolar level. Acs Sens. 2020;5:1427–35.PubMedCrossRef
111.
Lu P, Chen J, Li Z, Li Z, Zhang J, Kan B, et al. Visual identification and serotyping of toxigenic Vibrio cholerae serogroups O1 and O139 with CARID. Front Cell Infect Microbiol. 2022;12: 863435.PubMedPubMedCentralCrossRef
112.
Xiao X, Lin Z, Huang X, Lu J, Zhou Y, Zheng L, et al. Rapid and sensitive detection of Vibrio vulnificus using CRISPR/Cas12a combined with a recombinase-aided amplification assay. Front Microbiol. 2021;12: 767315.PubMedPubMedCentralCrossRef
113.
Qiu E, Jin S, Xiao Z, Chen Q, Wang Q, Liu H, et al. CRISPR-based Detection of Helicobacter pylori in Stool Samples. Helicobacter. 2021;26: e12828.PubMedCrossRef
114.
Li C, Chen X, Wen R, Ma P, Gu K, Li C, et al. Immunocapture magnetic beads enhanced the LAMP-CRISPR/Cas12a method for the sensitive, specific, and visual detection of Campylobacter jejuni. Biosensors. 2022;12:154.PubMedPubMedCentralCrossRef
115.
Wu H, Cao X, Meng Y, Richards D, Wu J, Ye Z, et al. DropCRISPR: a LAMP-Cas12a based digital method for ultrasensitive detection of nucleic acid. Biosens Bioelectron. 2022;211: 114377.PubMedCrossRef
116.
Schultzhaus Z, Wang Z, Stenger D. Systematic analysis, identification, and use of CRISPR/Cas13a–associated crRNAs for sensitive and specific detection of the lcrV gene of Yersinia pestis. Diagn Microbiol Infect Dis. 2021;99: 115275.PubMedCrossRef
117.
Gootenberg JS, Abudayyeh OO, Lee JW, Essletzbichler P, Dy AJ, Joung J, et al. Nucleic acid detection with CRISPR-Cas13a/C2c2. Science. 2017;356:438–42.PubMedPubMedCentralCrossRef
118.
Zhou J, Yin L, Dong Y, Peng L, Liu G, Man S, et al. CRISPR-Cas13a based bacterial detection platform: sensing pathogen Staphylococcus aureus in food samples. Anal Chim Acta. 2020;1127:225–33.PubMedCrossRef
119.
120.
Gao S, Liu J, Li Z, Ma Y, Wang J. Sensitive detection of foodborne pathogens based on CRISPR-Cas13a. J Food Sci. 2021;86:2615–25.PubMedCrossRef
121.
Song F, Wei Y, Wang P, Ge X, Li C, Wang A, et al. Combining tag-specific primer extension and magneto-DNA system for Cas14a-based universal bacterial diagnostic platform. Biosens Bioelectron. 2021;185: 113262.PubMedCrossRef
122.
123.
Chinese Medical Association. Species-specific Bacterial Detector for Fast Pathogen Diagnosis of Severe Pneumonia Patients in Intensive Care Uint: a Multicentre, Randomised Controlled Trial [Internet]. clinicaltrials.gov; 2022 May. Report No.: NCT05143593. Available from: https://​clinicaltrials.​gov/​study/​NCT05143593
124.
125.
126.
127.
Children’s Hospital of Fudan University. Establishment a Nucleic Acid Rapid Detection Technology Platform for Detecting Pathogenic Bordetella and Its Drug Resistance Genes [Internet]. clinicaltrials.gov; 2022 Sep. Report No.: NCT04535505. Available from: https://​clinicaltrials.​gov/​study/​NCT04535505
Metadata
Title
CRISPR-Cas System: A New Dawn to Combat Antibiotic Resistance
Authors
Muhammad Shahzad Rafiq
Muhammad AbuBakar Shabbir
Ahmed Raza
Shoaib Irshad
Andleeb Asghar
Muhammad Kashif Maan
Mushtaq Ahmed Gondal
Haihong Hao
Publication date
11-04-2024
Publisher
Springer International Publishing
Keyword
Antibiotic
Published in
BioDrugs / Issue 3/2024
Print ISSN: 1173-8804
Electronic ISSN: 1179-190X
DOI
https://doi.org/10.1007/s40259-024-00656-3

Other articles of this Issue 3/2024

Additional Data in Expanded Patient Populations and New Indications Support the Practice of Biosimilar-to-Biosimilar Switching

Consensus-Based Overarching Principles and Recommendations on the Use of Biosimilars in the Treatment of Inflammatory Arthritis in the Gulf Region

  • Open Access
  • Arthritis
  • Original Research Article

Targeted Gene Insertion: The Cutting Edge of CRISPR Drug Development with Hemophilia as a Highlight

Research Advances in Stem Cell Therapy for Erectile Dysfunction

Impact of Early Access Reform on Oncology Innovation in France: Approvals, Patients, and Costs

  • Original Research Article

Safety of Biological Therapies for Severe Asthma: An Analysis of Suspected Adverse Reactions Reported in the WHO Pharmacovigilance Database